Novo Nordisk A/S is to use artificial intelligence and real-world data to discover new drugs for cardiometabolic diseases under a collaboration with Valo Health Inc, a three-year old US company founded by venture capitalists. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
